Histogenics Corporation (HSGX) to Release Quarterly Earnings on Thursday
Histogenics Corporation (NASDAQ:HSGX) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 9th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.
Histogenics Corporation (NASDAQ:HSGX) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.06. During the same period in the prior year, the business earned ($0.61) EPS. On average, analysts expect Histogenics Corporation to post $-1.09 EPS for the current fiscal year and $-0.59 EPS for the next fiscal year.
TRADEMARK VIOLATION NOTICE: “Histogenics Corporation (HSGX) to Release Quarterly Earnings on Thursday” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/02/histogenics-corporation-hsgx-to-release-quarterly-earnings-on-thursday.html.
A number of research analysts have commented on the company. Zacks Investment Research cut Histogenics Corporation from a “buy” rating to a “hold” rating in a research note on Saturday, September 9th. HC Wainwright set a $4.00 price target on Histogenics Corporation and gave the stock a “buy” rating in a research note on Friday, August 11th. ValuEngine cut Histogenics Corporation from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th. Finally, Canaccord Genuity restated a “buy” rating and set a $4.00 price target on shares of Histogenics Corporation in a research note on Friday, August 11th.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.